{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:09:36Z","timestamp":1788772176744,"version":"build-2803163510"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,7]]},"DOI":"10.7759\/cureus.115882","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T08:31:29Z","timestamp":1788769889000},"source":"Crossref","is-referenced-by-count":0,"title":["Guillain-Barr\u00e9 Syndrome As the Initial Manifestation of Human Immunodeficiency Virus Infection: A Case Report"],"prefix":"10.7759","author":[{"given":"Ana","family":"Albuquerque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odete","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Claudia","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Magno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"397","author":"Shahrizaila N","year":"2021","unstructured":"Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barr\u00e9 syndrome. Lancet. 2021, 397:1214-28. 10.1016\/S0140-6736(21)00517-1","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard SE","year":"2019","unstructured":"Leonhard SE, Mandarakas MR, Gondim FA, et al.. Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps. Nat Rev Neurol. 2019, 15:671-83. 10.1038\/s41582-019-0250-9","journal-title":"Nat Rev Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12030907","article-title":"The peculiarity of infection and immunity correlated with Guillain-Barr\u00e9 syndrome in the HIV-infected population","volume":"12","author":"Wang Y","year":"2023","unstructured":"Wang Y, Yang J, Wen Y. The peculiarity of infection and immunity correlated with Guillain-Barr\u00e9 syndrome in the HIV-infected population. J Clin Med. 2023, 12:907. 10.3390\/jcm12030907","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(02)00418-5","article-title":"HIV-associated Guillain-Barr\u00e9 syndrome","volume":"208","author":"Brannagan TH III","year":"2003","unstructured":"Brannagan TH III, Zhou Y. HIV-associated Guillain-Barr\u00e9 syndrome. J Neurol Sci. 2003, 208:39-42. 10.1016\/S0022-510X(02)00418-5","journal-title":"J Neurol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02350-1","article-title":"Guillain-Barr\u00e9 syndrome as the first presentation of human immunodeficiency virus infection","volume":"21","author":"Lopes M","year":"2021","unstructured":"Lopes M, Marques P, Silva B, et al.. Guillain-Barr\u00e9 syndrome as the first presentation of human immunodeficiency virus infection. BMC Neurol. 2021, 21:321. 10.1186\/s12883-021-02350-1","journal-title":"BMC Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2022.102368","article-title":"Guillain-Barr\u00e9 syndrome spectrum as manifestation of HIV-related immune reconstitution inflammatory syndrome: case report and literature review","volume":"26","author":"Vidal JE","year":"2022","unstructured":"Vidal JE, Guedes BF, Gomes HR, Mendon\u00e7a RH. Guillain-Barr\u00e9 syndrome spectrum as manifestation of HIV-related immune reconstitution inflammatory syndrome: case report and literature review. Braz J Infect Dis. 2022, 26:102368. 10.1016\/j.bjid.2022.102368","journal-title":"Braz J Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12594","article-title":"European Academy of Neurology\/peripheral nerve Society guideline on diagnosis and treatment of Guillain-Barr\u00e9 syndrome","volume":"28","author":"van Doorn PA","year":"2023","unstructured":"van Doorn PA, Van den Bergh PY, Hadden RD, et al.. European Academy of Neurology\/peripheral nerve Society guideline on diagnosis and treatment of Guillain-Barr\u00e9 syndrome. J Peripher Nerv Syst. 2023, 28:535-63. 10.1111\/jns.12594","journal-title":"J Peripher Nerv Syst"},{"key":"ref8","article-title":"Revised surveillance case definition for HIV infection--United States, 2014","volume":"63","year":"2014","unstructured":"Revised surveillance case definition for HIV infection--United States, 2014. MMWR Recomm Rep. 2014, 63.1-10.","journal-title":"MMWR Recomm Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually transmitted infections treatment guidelines, 2021","volume":"70","author":"Workowski KA","year":"2021","unstructured":"Workowski KA, Bachmann LH, Chan PA, et al.. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021, 70:1-187. 10.15585\/mmwr.rr7004a1","journal-title":"MMWR Recomm Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.54.11.957","article-title":"Treatment related fluctuations in Guillain-Barr\u00e9 syndrome after high-dose immunoglobulins or plasma-exchange","volume":"54","author":"Kleyweg RP","year":"1991","unstructured":"Kleyweg RP, van der Mech\u00e9 FG. Treatment related fluctuations in Guillain-Barr\u00e9 syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry. 1991, 54:957-60. 10.1136\/jnnp.54.11.957","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30494-4","article-title":"Second intravenous immunoglobulin dose in patients with Guillain-Barr\u00e9 syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial","volume":"20","author":"Walgaard C","year":"2021","unstructured":"Walgaard C, Jacobs BC, Lingsma HF, et al.. Second intravenous immunoglobulin dose in patients with Guillain-Barr\u00e9 syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2021, 20:275-83. 10.1016\/S1474-4422(20)30494-4","journal-title":"Lancet Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/528515-guillain-barr-syndrome-as-the-initial-manifestation-of-human-immunodeficiency-virus-infection-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T08:31:30Z","timestamp":1788769890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/528515-guillain-barr-syndrome-as-the-initial-manifestation-of-human-immunodeficiency-virus-infection-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.115882","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,7]]}}}